Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$4.18
+0.07 (+1.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 13%
FCF escenarios
weak_data · normalized FCF $-107.1M · quality 34.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
2/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-525.8%
↓Gross Margin
24.8%
↓Debt/Equity
36.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-22.4%
FCF CAGR
—
FCF margin
-7.6%
FCF / Net income
0.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $831.2M · net income $-430.0M · FCF $-63.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $831.2M | $831.2M | $990.7M | $1.48B | $1.78B |
| Net Income | $-430.0M | $-430.0M | $-1.53B | $-106.5M | $10.5M |
| EBITDA | $-23.1M | $-23.1M | $-1.21B | $218.4M | $312.5M |
| EPS | -0.33 | -0.33 | -1.18 | -0.08 | 0.01 |
| Gross Margin | 24.8% | 24.8% | 35.2% | 38.6% | 43.2% |
| Operating Margin | -23.6% | -23.6% | -20.3% | -1.3% | -0.1% |
| Net Margin | -51.7% | -51.7% | -154.0% | -7.2% | 0.6% |
| Balance Sheet | |||||
| Debt/Equity | 36.25 | 36.25 | 6.57 | 1.63 | 1.57 |
| Current Ratio | 0.31 | 0.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-63.4M | $-63.4M | $-193.1M | $-107.1M | $-121.6M |
| Returns | |||||
| ROE | -525.8% | -525.8% | -290.4% | -5.2% | 0.5% |
| Valuation | |||||
| P/E | — | — | — | — | 522.22 |
| EV/EBITDA | — | — | — | 40.45 | 27.17 |
| P/B | 66.32 | 66.32 | 10.74 | 2.83 | 2.53 |
| Growth & Yield | |||||
| Revenue Growth | -16.1% | -16.1% | -33.0% | -16.9% | — |
| EPS Growth | 71.8% | 71.8% | -1331.9% | -1113.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.18 → -0.33
Residual
-26.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.